Verus Capital Partners LLC Sells 120 Shares of Axon Enterprise, Inc $AXON

Verus Capital Partners LLC lowered its holdings in Axon Enterprise, Inc (NASDAQ:AXON) by 28.2% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 305 shares of the biotechnology company’s stock after selling 120 shares during the quarter. Verus Capital Partners LLC’s holdings in Axon Enterprise were worth $253,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors also recently modified their holdings of AXON. TCI Wealth Advisors Inc. bought a new stake in Axon Enterprise in the 2nd quarter worth approximately $214,000. Duncker Streett & Co. Inc. boosted its stake in shares of Axon Enterprise by 3.2% in the 2nd quarter. Duncker Streett & Co. Inc. now owns 14,501 shares of the biotechnology company’s stock worth $12,006,000 after buying an additional 448 shares during the last quarter. EFG Asset Management North America Corp. grew its holdings in shares of Axon Enterprise by 17.8% in the second quarter. EFG Asset Management North America Corp. now owns 12,701 shares of the biotechnology company’s stock worth $10,511,000 after acquiring an additional 1,918 shares during the period. New York Life Investment Management LLC increased its position in Axon Enterprise by 3.2% during the second quarter. New York Life Investment Management LLC now owns 11,044 shares of the biotechnology company’s stock valued at $9,144,000 after acquiring an additional 341 shares during the last quarter. Finally, Sivia Capital Partners LLC bought a new position in Axon Enterprise in the second quarter valued at about $284,000. 79.08% of the stock is owned by hedge funds and other institutional investors.

Axon Enterprise Trading Down 0.5%

Axon Enterprise stock opened at $569.51 on Thursday. Axon Enterprise, Inc has a 12-month low of $469.24 and a 12-month high of $885.91. The firm has a market capitalization of $44.94 billion, a price-to-earnings ratio of 140.62, a P/E/G ratio of 29.49 and a beta of 1.45. The firm has a 50 day moving average of $709.82 and a 200 day moving average of $735.72. The company has a current ratio of 2.95, a quick ratio of 2.71 and a debt-to-equity ratio of 0.63.

Axon Enterprise (NASDAQ:AXON) last issued its quarterly earnings results on Tuesday, November 4th. The biotechnology company reported $1.17 earnings per share for the quarter, missing the consensus estimate of $1.63 by ($0.46). The firm had revenue of $710.64 million for the quarter, compared to analysts’ expectations of $704.83 million. Axon Enterprise had a net margin of 13.64% and a return on equity of 6.80%. Axon Enterprise’s revenue for the quarter was up 30.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.45 EPS. Axon Enterprise has set its Q4 2025 guidance at EPS. FY 2025 guidance at EPS. As a group, research analysts predict that Axon Enterprise, Inc will post 5.8 earnings per share for the current year.

Insider Buying and Selling

In other Axon Enterprise news, CAO Jennifer H. Mak sold 77 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $760.00, for a total value of $58,520.00. Following the completion of the sale, the chief accounting officer owned 15,003 shares in the company, valued at approximately $11,402,280. This represents a 0.51% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction dated Monday, September 8th. The shares were sold at an average price of $743.64, for a total value of $7,436,400.00. Following the sale, the chief executive officer directly owned 3,043,982 shares in the company, valued at approximately $2,263,626,774.48. This represents a 0.33% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 52,041 shares of company stock worth $36,794,077 in the last three months. Corporate insiders own 5.70% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on AXON shares. Northland Securities set a $800.00 price target on Axon Enterprise in a research note on Tuesday, August 5th. Raymond James Financial reissued an “outperform” rating and issued a $855.00 price objective (up previously from $645.00) on shares of Axon Enterprise in a report on Tuesday, August 5th. Barclays cut their target price on shares of Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Zacks Research downgraded shares of Axon Enterprise from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 2nd. Finally, Piper Sandler dropped their price target on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 5th. Fourteen analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, Axon Enterprise has an average rating of “Moderate Buy” and an average price target of $810.71.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.